Advertisement

Rheumatology International

, Volume 33, Issue 11, pp 2943–2948 | Cite as

Is Helicobacter pylori infection a risk factor for disease severity in systemic sclerosis?

  • Mislav RadićEmail author
  • Dušanka Martinović Kaliterna
  • Damir Bonacin
  • Jadranka Morović Vergles
  • Josipa Radić
  • Damir Fabijanić
  • Vedran Kovačić
Short Communication

Abstract

Helicobacter pylori (H. pylori) is suspected to be one of the factors triggering systemic sclerosis (SSc). Data on the possible role of H. pylori are lacking. The aim of this study was to assess the effect of H. pylori infection in SSc patients. Forty-two SSc patients without dyspeptic symptoms were recruited—26 were H. pylori-positive and 16 were H. pylori-negative on the basis of invasive test. We evaluated the disease severity using clinical and laboratory parameters according to the Medsger Severity Scale. The level of SSc activity was evaluated according to Valentini activity score. The prevalence of H. pylori infection in population of SSc patients is 62 %. Severity of skin, gastrointestinal, and joint/tendon involvement was different between H. pylori-positive and -negative SSc patients (p < 0.001 for skin involvement, p = 0.002 and p = 0.03 for gastrointestinal and joint/tendon involvement, respectively) as well as erythrocyte sedimentation rate (p = 0.002). Severity score according to Medsger was higher in the H. pylori-positive than in the H. pylori-negative SSc patients (p < 0.001). Our data suggest that H. pylori infection correlates with severity of skin, gastrointestinal, and joint/tendon involvement in SSc patients. H. pylori-positive SSc patients showed higher severity score compared to H. pylori-negative. Therefore, H. pylori infection may play a role in the pathogenesis of SSc and also can provide some prognostic information.

Keywords

Systemic sclerosis Helicobacter pylori Disease activity Disease severity 

References

  1. 1.
    Seibold JR (2005) Scleroderma. In: Harris JR Jr, Budd RC, Firestein GS et al (eds) Kelley’s textbook’s of rheumatology, 7th edn. Elsevier Saunders, Philadelphia, pp 1279–1308Google Scholar
  2. 2.
    Radic M, Martinovic Kaliterna D, Radic J (2010) Infectious disease as aetiological factor in the pathogenesis of systemic sclerosis. Neth J Med 68:348–353PubMedGoogle Scholar
  3. 3.
    Amedei A, Bergman MP, Appelmelk BJ et al (2003) Molecular mimicry between Helicobacter pylori antigens and H+, K+-adenosine triphosphatase in human gastric autoimmunity. J Exp Med 198:1147–1156PubMedCrossRefGoogle Scholar
  4. 4.
    Yamanishi S, Iizumi T, Watanabe E et al (2006) Implications for induction of autoimmunity via activation of B-1 cells by Helicobacter pylori urease. Infect Immun 74:248–256PubMedCrossRefGoogle Scholar
  5. 5.
    Aragona P, Magazzu G, Macchia G et al (1999) Presence of antibodies against Helicobacter pylori and its heat-shock protein 60 in the serum of patients with Sjögren’s syndrome. J Rheumatol 26:1306–1311PubMedGoogle Scholar
  6. 6.
    Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic, Therapeutic Criteria Committee (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581–590CrossRefGoogle Scholar
  7. 7.
    LeRoy EC, Black CM, Fleischmajer R et al (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15:202–205PubMedGoogle Scholar
  8. 8.
    Medsger TA Jr, Bombardieri S, Czirjak L, Scorza R, Della Rossa A, Bencivelli W (2003) Assessment of disease severity and prognosis. Clin Exp Rheumatol 21(Suppl 29):S42–S46PubMedGoogle Scholar
  9. 9.
    Valentini G, Della Rossa A, Bombardieri S et al (2001) European multicentre study to define disease activity for systemic sclerosis. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis 60:592–598PubMedCrossRefGoogle Scholar
  10. 10.
    Amital H, Govoni M, Maya R et al (2008) Role of infectious agents in systemic rheumatic diseases. Clin Exp Rheumatol 25(27):32Google Scholar
  11. 11.
    Ebert EC (2008) Gastric and enteric involvement in progressive systemic sclerosis. J Clin Gastroenterol 42:5–12PubMedCrossRefGoogle Scholar
  12. 12.
    Ando T, Minami M, Ishiguro K et al (2006) Changes in biochemical parameters related to atherosclerosis after Helicobacter pylori eradication. Aliment Pharmacol Ther 24(Suppl 4):58–64Google Scholar
  13. 13.
    Danese S, Zoli A, Cremonini F, Gasbarrini A (2000) High prevalence of Helicobacter pylori type I virulent strains in patients with systemic sclerosis. J Rheumatol 27:1568–1569PubMedGoogle Scholar
  14. 14.
    Radić M, Kaliterna DM, Bonacin D, Morović Vergles J, Radić J (2010) Correlation between Helicobacter pylori infection and systemic sclerosis activity. Rheumatology (Oxford) 49:1784–1785CrossRefGoogle Scholar
  15. 15.
    Babus V, Presecki V, Katicic M et al (1997) Distribution of Helicobacter pylori infection in the adult population of Croatia. Liječ Vjesn 119:139–142PubMedGoogle Scholar
  16. 16.
    Pounder RE, Ng D (1995) The prevalence of Helicobacter pylori infection in different countries. Aliment Pharmacol Ther 9:33–39PubMedGoogle Scholar
  17. 17.
    Hamamdzic D, Kasman LM, LeRoy EC (2002) The role of infectious agents in the pathogenesis of systemic sclerosis. Curr Opin Rheumatol 14:694–698PubMedCrossRefGoogle Scholar
  18. 18.
    Radić M, Kaliterna DM, Radić J (2011) Helicobacter pylori infection and systemic sclerosis—is there a link? Joint Bone Spine 78:337–340PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • Mislav Radić
    • 1
    Email author
  • Dušanka Martinović Kaliterna
    • 1
  • Damir Bonacin
    • 2
  • Jadranka Morović Vergles
    • 3
  • Josipa Radić
    • 4
  • Damir Fabijanić
    • 5
  • Vedran Kovačić
    • 4
  1. 1.Department of Rheumatology and Clinical ImmnulogyUniversity Hospital SplitSplitCroatia
  2. 2.Department of GastroenterologyUniversity Hospital SplitSplitCroatia
  3. 3.Department of Rheumatology and Clinical ImmunologyDubrava University HospitalZagrebCroatia
  4. 4.Department of NephrologyUniversity Hospital SplitSplitCroatia
  5. 5.Department of CardiologyUniversity Hospital SplitSplitCroatia

Personalised recommendations